BioSpace News Archive

Pyxis Oncology, Inc. announced the departure of Ronald Herbst, Ph.D., as the Company’s Chief Scientific Officer and the appointment of Jan Pinkas, Ph.D., currently Senior Vice President, Preclinical Research & Development, to the position of Chief Scientific Officer.

Mallinckrodt plc announced the publication of findings from a retrospective chart review study assessing the real-world use and outcomes of INOmax® gas, for inhalation therapy in hospitalized patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome, a disorder in which fluid leaks into the lungs, making breathing difficult or impossible.

SOPHiA GENETICS SA today announced it will release its financial results for the first quarter of fiscal 2022 before U.S. markets open on Tuesday, May 10, 2022.

Ikena Oncology, Inc. today announced the appointment of Jotin Marango, M.D., Ph.D., to Chief Financial Officer (CFO) and Head of Corporate Development.

VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’).

Glaukos Corporation plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022.

LENZ Therapeutics today announced that it has entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China.

Sonnet BioTherapeutics Holdings, Inc., announced today that dosing has been initiated in a Phase 1 clinical trial of SON-1010 (IL12-F H AB) in adult patients with advanced solid tumors.

9 Meters Biopharma, Inc. announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 16/781,304 is allowed.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, Prospera™ Heart, has been published in the Journal of Heart and Lung Transplantation - a leading journal with the highest impact factor in the transplantation sector.